CytoMed Therapeutics (GDTC) Competitors $2.33 -0.09 (-3.72%) (As of 10:43 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsShort InterestTrends GDTC vs. VERU, KPTI, ADAG, TLSA, ANVS, RLMD, GNLX, ORMP, AVTX, and GBIOShould you be buying CytoMed Therapeutics stock or one of its competitors? The main competitors of CytoMed Therapeutics include Veru (VERU), Karyopharm Therapeutics (KPTI), Adagene (ADAG), Tiziana Life Sciences (TLSA), Annovis Bio (ANVS), Relmada Therapeutics (RLMD), Genelux (GNLX), Oramed Pharmaceuticals (ORMP), Avalo Therapeutics (AVTX), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry. CytoMed Therapeutics vs. Veru Karyopharm Therapeutics Adagene Tiziana Life Sciences Annovis Bio Relmada Therapeutics Genelux Oramed Pharmaceuticals Avalo Therapeutics Generation Bio Veru (NASDAQ:VERU) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Do institutionals & insiders believe in VERU or GDTC? 47.2% of Veru shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to VERU or GDTC? In the previous week, Veru had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for Veru and 1 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 1.87 beat Veru's score of 0.94 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Veru Positive CytoMed Therapeutics Very Positive Which has better earnings and valuation, VERU or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than Veru. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeru$16.30M6.24-$93.15M-$0.48-1.45CytoMed TherapeuticsN/AN/A-$3.13MN/AN/A Which has more volatility & risk, VERU or GDTC? Veru has a beta of -0.5, indicating that its stock price is 150% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Is VERU or GDTC more profitable? CytoMed Therapeutics has a net margin of 0.00% compared to Veru's net margin of -376.38%. CytoMed Therapeutics' return on equity of 0.00% beat Veru's return on equity.Company Net Margins Return on Equity Return on Assets Veru-376.38% -115.99% -66.94% CytoMed Therapeutics N/A N/A N/A Does the MarketBeat Community favor VERU or GDTC? Veru received 267 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 69.67% of users gave Veru an outperform vote. CompanyUnderperformOutperformVeruOutperform Votes27169.67% Underperform Votes11830.33% CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Do analysts rate VERU or GDTC? Veru currently has a consensus price target of $4.00, suggesting a potential upside of 475.71%. CytoMed Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 106.28%. Given Veru's higher possible upside, equities research analysts clearly believe Veru is more favorable than CytoMed Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veru 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVeru and CytoMed Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get CytoMed Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GDTC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GDTC vs. The Competition Export to ExcelMetricCytoMed TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.71M$6.73B$5.23B$8.96BDividend YieldN/A7.94%5.24%4.05%P/E RatioN/A5.7998.6914.63Price / SalesN/A381.601,484.9296.07Price / CashN/A62.3741.8238.51Price / Book3.118.116.116.18Net Income-$3.13M$152.00M$117.65M$224.75M7 Day Performance8.70%3.31%2.86%1.98%1 Month Performance5.16%-1.52%1.79%9.78%1 Year Performance-31.16%31.57%35.89%29.97% CytoMed Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GDTCCytoMed Therapeutics2.4726 of 5 stars$2.33-3.7%$5.00+114.6%-31.3%$25.49MN/A0.00N/APositive NewsVERUVeru2.0107 of 5 stars$0.72+1.1%$4.00+459.0%-31.2%$104.74M$16.30M0.00189Gap UpKPTIKaryopharm Therapeutics3.9869 of 5 stars$0.82-2.5%$5.00+506.8%+4.4%$103.26M$146.03M-0.74380Short Interest ↑ADAGAdagene3.1904 of 5 stars$2.31-1.3%$5.00+116.5%+44.1%$102.27M$815,746.000.00260Positive NewsTLSATiziana Life Sciences0.6646 of 5 stars$0.94-0.9%N/A+58.8%$99.53MN/A0.008Positive NewsGap DownANVSAnnovis Bio2.39 of 5 stars$7.20+7.3%$32.17+346.8%-14.3%$99.34MN/A-1.613RLMDRelmada Therapeutics4.3831 of 5 stars$3.29+8.9%$7.50+128.0%+31.1%$99.27MN/A-1.1310Positive NewsGNLXGenelux2.0525 of 5 stars$2.86+6.3%$18.25+538.1%-78.7%$98.78M$170,000.00-2.8310Positive NewsORMPOramed Pharmaceuticals1.8166 of 5 stars$2.43+2.5%N/A+15.7%$97.95M$1.34M21.5510Analyst DowngradeNews CoverageAVTXAvalo Therapeutics2.0836 of 5 stars$9.41-1.5%N/A-37.0%$97.81M$820,000.000.0040Positive NewsGap DownGBIOGeneration Bio3.6723 of 5 stars$1.46-3.9%$7.50+413.7%+2.2%$97.52M$18.58M-0.66150Short Interest ↓ Related Companies and Tools Related Companies VERU Competitors KPTI Competitors ADAG Competitors TLSA Competitors ANVS Competitors RLMD Competitors GNLX Competitors ORMP Competitors AVTX Competitors GBIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GDTC) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytoMed Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share CytoMed Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
